Free Trial

Relay Therapeutics (RLAY) News Today

→ A Wave of Creative Destruction Set to Strike June 30 (From Banyan Hill Publishing) (Ad)
Free RLAY Stock Alerts
$7.90
+0.63 (+8.67%)
(As of 06/7/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends
June 8 at 5:21 AM | americanbankingnews.com
HC Wainwright Reiterates Buy Rating for Relay Therapeutics (NASDAQ:RLAY)
June 7 at 8:10 AM | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Receives Buy Rating from HC Wainwright
HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of Relay Therapeutics in a research note on Friday.
June 7 at 2:06 AM | americanbankingnews.com
Relay Therapeutics (NASDAQ:RLAY) versus Organovo (NASDAQ:ONVO) Critical Survey
June 6 at 8:18 AM | insidertrades.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Peter Rahmer Sells 19,864 Shares
June 6 at 7:38 AM | insidertrades.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) Insider Peter Rahmer Sells 20,450 Shares
June 6 at 7:00 AM | globenewswire.com
Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
June 5 at 10:27 PM | marketbeat.com
Peter Rahmer Sells 19,864 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock
Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) insider Peter Rahmer sold 19,864 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $6.47, for a total transaction of $128,520.08. Following the transaction, the insider now owns 493,470 shares in the company, valued at $3,192,750.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
June 5 at 4:05 PM | globenewswire.com
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
June 5 at 10:29 AM | marketbeat.com
Affinity Asset Advisors LLC Acquires Shares of 300,000 Relay Therapeutics, Inc. (NASDAQ:RLAY)
Affinity Asset Advisors LLC acquired a new stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 300,000 shares of the company's
June 4, 2024 | marketbeat.com
Rhenman & Partners Asset Management AB Buys 200,000 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY)
Rhenman & Partners Asset Management AB grew its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 105.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 390,000 shares of the company's stoc
June 3, 2024 | marketbeat.com
Finepoint Capital LP Has $14.51 Million Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)
Finepoint Capital LP boosted its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 51.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,317,870 shares of the company's stock after purchasing an additional 447,
June 3, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Trading 11.9% Higher
Relay Therapeutics (NASDAQ:RLAY) Trading 11.9% Higher
June 1, 2024 | marketbeat.com
3,068,973 Shares in Relay Therapeutics, Inc. (NASDAQ:RLAY) Purchased by Norges Bank
Norges Bank acquired a new position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 3,068,973 shares of the company's stock, valued at approximately $33,789,000. Norges Bank owned approximately
May 31, 2024 | americanbankingnews.com
Relay Therapeutics (NASDAQ:RLAY) Trading Down 6.5%
May 31, 2024 | marketbeat.com
Charles Schwab Investment Management Inc. Has $9.67 Million Position in Relay Therapeutics, Inc. (NASDAQ:RLAY)
Charles Schwab Investment Management Inc. lifted its holdings in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 22.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 877,813 s
May 31, 2024 | americanbankingnews.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of "Buy" by Analysts
May 29, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Shares Down 6.5%
Relay Therapeutics (NASDAQ:RLAY) Shares Down 6.5%
May 21, 2024 | globenewswire.com
Relay Therapeutics to Participate in Upcoming Investor Conferences
May 21, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Trading Up 5.3%
Relay Therapeutics (NASDAQ:RLAY) Trading Up 5.3%
May 20, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 2.7%
Relay Therapeutics (NASDAQ:RLAY) Shares Down 2.7%
May 13, 2024 | globenewswire.com
Relay Therapeutics to Host New Program and Platform Event on June 6, 2024
May 10, 2024 | msn.com
Relay Therapeutics upgraded by Barclays ahead of data readout
May 10, 2024 | msn.com
Barclays Upgrades Relay Therapeutics (RLAY)
May 10, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Raised to "Overweight" at Barclays
Barclays raised Relay Therapeutics from an "equal weight" rating to an "overweight" rating and set a $15.00 price objective for the company in a report on Friday.
May 8, 2024 | markets.businessinsider.com
Optimistic Buy Rating for Relay Therapeutics: Pipeline Progress and Financial Stability Drive Analyst Confidence
May 7, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Trading Down 5.2%
Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 5.2%
May 6, 2024 | marketbeat.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) Receives Consensus Recommendation of "Buy" from Analysts
Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) have earned a consensus rating of "Buy" from the six ratings firms that are presently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy rating. The average 12 month price target among anal
May 4, 2024 | finance.yahoo.com
Relay Therapeutics First Quarter 2024 Earnings: Beats Expectations
May 3, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Posts Quarterly Earnings Results
Relay Therapeutics (NASDAQ:RLAY - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.70) by $0.08. The firm had revenue of $10.01 million during the quarter, compared to analyst estimates of $0.12 million. Relay Therapeutics had a negative return on equity of 42.43% and a negative net margin of 1,263.49%. The firm's quarterly revenue was up 4327.9% on a year-over-year basis. During the same period last year, the company posted ($0.78) EPS.
May 3, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Up on Earnings Beat
Relay Therapeutics (NASDAQ:RLAY) Shares Gap Up After Earnings Beat
May 2, 2024 | finance.yahoo.com
Relay Therapeutics Outperforms Revenue Expectations in Q1 2024
May 2, 2024 | investorplace.com
RLAY Stock Earnings: Relay Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 2, 2024 | globenewswire.com
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
April 30, 2024 | insidertrades.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo Sells 1,695 Shares
April 29, 2024 | marketbeat.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Sells $10,814.10 in Stock
Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) CFO Thomas Catinazzo sold 1,695 shares of Relay Therapeutics stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $6.38, for a total value of $10,814.10. Following the completion of the transaction, the chief financial officer now owns 339,803 shares of the company's stock, valued at approximately $2,167,943.14. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
April 26, 2024 | marketbeat.com
Relay Therapeutics (RLAY) Scheduled to Post Earnings on Thursday
Relay Therapeutics (NASDAQ:RLAY) will be releasing earnings after the market closes on Thursday, May 2, Zacks reports.
April 25, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Shares Down 7.6%
Relay Therapeutics (NASDAQ:RLAY) Trading Down 7.6%
April 25, 2024 | globenewswire.com
Relay Therapeutics to Announce First Quarter 2024 Financial Results and Corporate Highlights on May 2, 2024
April 24, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Hits New 52-Week Low at $5.74
Relay Therapeutics (NASDAQ:RLAY) Reaches New 1-Year Low at $5.74
April 18, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Sets New 52-Week Low at $5.95
Relay Therapeutics (NASDAQ:RLAY) Hits New 52-Week Low at $5.95
April 17, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Trading Down 4.9%
Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.9%
April 11, 2024 | globenewswire.com
Relay Therapeutics to Participate in Upcoming Investor Conferences
April 11, 2024 | marketbeat.com
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Rating of "Moderate Buy" by Brokerages
Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten analysts that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and o
April 3, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Trading Down 3.3%
Relay Therapeutics (NASDAQ:RLAY) Trading Down 3.3%
March 27, 2024 | marketbeat.com
Relay Therapeutics (NASDAQ:RLAY) Trading Up 6.2%
Relay Therapeutics (NASDAQ:RLAY) Shares Up 6.2%
March 19, 2024 | markets.businessinsider.com
Strong Buy Rating for Relay Therapeutics Amid Pipeline Progress and Strategic Direction
March 19, 2024 | marketbeat.com
Leerink Partnrs Comments on Relay Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:RLAY)
Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - Leerink Partnrs issued their Q2 2024 earnings per share estimates for Relay Therapeutics in a research note issued on Sunday, March 17th. Leerink Partnrs analyst A. Berens expects that the company will post earnings of ($0.64) per share for t
March 16, 2024 | finance.yahoo.com
RLAY Apr 2024 7.500 call
March 16, 2024 | finance.yahoo.com
RLAY Apr 2024 7.500 put
March 15, 2024 | investorplace.com
3 Precision Medicine Stocks That Could Benefit From the Industry's Rise
Get Relay Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.

A Wave of Creative Destruction Set to Strike June 30 (Ad)

You have until June 30 … then all hell will begin to break loose… The White House and Goldman Sachs predict generative AI will soon replace up to 300 MILLION jobs — one in every four careers … worldwide.

Click here for details. 

RLAY Media Mentions By Week

RLAY Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RLAY
News Sentiment
▼
0.62

0.72
▲
Average
Medical
News Sentiment

RLAY News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RLAY Articles
This Week
▼
14

2
▲
RLAY Articles
Average Week

Get Relay Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:RLAY) was last updated on 6/8/2024 by MarketBeat.com Staff

From Our Partners
We’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How)
Bitcoin can and probably will hit the $1 MILLION level this decade. That’s more than 1,000% upside from the...
Paradigm Press | Sponsored
Breaking - The US Gov. Seized CITGO
Do you want an investment that can double or triple your money in the next three months? The US Court is cu...
Augury Research | Sponsored
Top 5 Tech Stocks to Buy for 2024
The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...
Daily Market Alerts | Sponsored
Top 5 AI Stocks to Buy for 2024
The electric vehicle boom is accelerating – and fast.
Market Moving Trends | Sponsored
No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free
Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...
Hedgeye | Sponsored
Was the Great Financial Crisis fun?
The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...
Brooks Enterprises | Sponsored
Collapse of the Petrodollar
The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...
Colonial Metals | Sponsored
Shocking $16T Elon Musk Crypto Leak
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...
Crypto 101 Media | Sponsored